About: Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Creator	Wang, Hao Chen, Fuxiang Guan, Fangxia Kaur, Gurbakhash Sankin, Alexander Zang, Xingxing
source	PMC
abstract	Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.
has issue date	2019-06-11(xsd:dateTime)
bibo:doi	10.1186/s13045-019-0746-1
bibo:pmid	31186046
has license	cc-by
sha1sum (hex)	962ac993935197113b1bd7beccf573a44918b12d
schema:url	https://doi.org/10.1186/s13045-019-0746-1
resource representing a document's title	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
has PubMed Central identifier	PMC6558778
has PubMed identifier	31186046
schema:publication	J Hematol Oncol
resource representing a document's body	covid:962ac993935197113b1bd7beccf573a44918b12d#body_text
is schema:about of	named entity 'subset' named entity 'cell therapy' named entity 'CD123' named entity 'BCMA' named entity 'immune' named entity 'blockade' named entity 'HERE' named entity 'therapy' named entity 'cancer' named entity 'partially' named entity 'PD-1' named entity 'CD38' named entity 'preclinical' named entity 'patients' named entity 'CD19' named entity 'based' named entity 'Tim-3' named entity 'CTLA-4' named entity 'safe and effective' named entity 'hematologic malignancies' named entity 'CD19' named entity 'hematologic malignancies' named entity 'CD123' named entity 'Galectin-9' named entity 'ICB' named entity 'ICB' named entity 'CAR-T cell therapy' named entity 'hematologic malignancies' named entity 'Immune checkpoint blockade' named entity 'targets' named entity 'bleomycin' named entity 'peptide' named entity 'CLL' named entity 'mouse model' named entity 'pembrolizumab' named entity 'protein' named entity 'LAG-3' named entity 'mice' named entity 'CD19' named entity 'LAG-3' named entity 'AML' named entity 'murine' named entity 'Siglec' named entity 'genetic alterations' named entity 'Th1 cells' named entity 'CAR-T therapy' named entity 'mice' named entity 'BCR/ABL' named entity 'AML' named entity 'CLL' named entity 'hematologic malignancies' named entity 'IFN-γ' named entity 'pembrolizumab' named entity 'CTLA-4' named entity 'tumor progression' named entity 'relapse' named entity 'self-renew' named entity 'PD-L1' named entity 'diagnostic marker' named entity 'PD-1' named entity 'angiopoietin-like proteins' named entity 'autocrine' named entity 'CD123' named entity 'NK cells' named entity 'FDA' named entity 'CD33' named entity 'SCT' named entity 'transcriptomic' named entity 'chemotherapy' named entity 'positively correlated' named entity 'CAR-T therapy' named entity 'CD3' named entity 'DLBCL' named entity 'CTLA-4' named entity 'hematologic malignancies' named entity 'CD38'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software